Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Intensity Therapeutics, Inc.
Xencor, Inc.
Bristol-Myers Squibb
Incyte Corporation
ExcellaBio LLC
Lytix Biopharma AS
Bristol-Myers Squibb